University of Dundee intelligent drug design spinout Exscientia has struck a business deal with Celgene after raising series B funding from the corporate in January.
Exscientia, a UK-based small molecule discovery technology spinout of University of Dundee, received $25m today through a three-year drug design collaboration with pharmaceutical developer Celgene.
The up-front payment could be augmented by additional funding on the fulfilment of milestones related to clinical, regulatory and commercial considerations.
Exscientia will also receive tiered royalties on any product sales resulting from the partnership, which will exploit the spinout’s artificial intelligence (AI)-powered Centaur Chemist platform to uncover small molecule candidates for three…
